CLOs on the Move

Karalex Pharma

www.karalexpharma.com

 
Karalex Pharma is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Kalypsys

Kalypsys is a clinical stage pharmaceutical company that is advancing the way drugs are discovered and developed. We seamlessly integrate our capabilities in drug discovery, medicinal chemistry and translational medicine with proprietary automated

CONSEJO COUNSELING & REFERRAL SERVICE

Consejo provides culturally competent behavioral health, substance abuse and domestic violence services to Latinos in King and Pierce Counties.

Tahiti Trade Super Nutaceuticals

Tahiti Trade Super Nutaceuticals is a Riverside, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

PamLab

Pamlab, L.L.C. is a company focused on the future. We lead the United States with use of novel folate therapies to lower homocysteine. We are looking for hard-working, motivated and optimistic individuals who would like a challenging career and are

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.